sterling pharma solutions limited Company Information
Company Number
05712796
Next Accounts
Dec 2025
Shareholders
saffron bidco limited
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
dudley, cramlington, northumberland, NE23 7QG
sterling pharma solutions limited Estimated Valuation
Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £308.6m based on a Turnover of £115.5m and 2.67x industry multiple (adjusted for size and gross margin).
sterling pharma solutions limited Estimated Valuation
Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £144m based on an EBITDA of £12.6m and a 11.44x industry multiple (adjusted for size and gross margin).
sterling pharma solutions limited Estimated Valuation
Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £90.4m based on Net Assets of £51.8m and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Sterling Pharma Solutions Limited Overview
Sterling Pharma Solutions Limited is a live company located in northumberland, NE23 7QG with a Companies House number of 05712796. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in February 2006, it's largest shareholder is saffron bidco limited with a 100% stake. Sterling Pharma Solutions Limited is a established, mega sized company, Pomanda has estimated its turnover at £115.5m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Sterling Pharma Solutions Limited Health Check
Pomanda's financial health check has awarded Sterling Pharma Solutions Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs


4 Strong

2 Regular

6 Weak

Size
annual sales of £115.5m, make it larger than the average company (£34.5m)
£115.5m - Sterling Pharma Solutions Limited
£34.5m - Industry AVG

Growth
3 year (CAGR) sales growth of 12%, show it is growing at a faster rate (5.5%)
12% - Sterling Pharma Solutions Limited
5.5% - Industry AVG

Production
with a gross margin of 26.3%, this company has a higher cost of product (35.8%)
26.3% - Sterling Pharma Solutions Limited
35.8% - Industry AVG

Profitability
an operating margin of 5.3% make it less profitable than the average company (7.4%)
5.3% - Sterling Pharma Solutions Limited
7.4% - Industry AVG

Employees
with 654 employees, this is above the industry average (116)
654 - Sterling Pharma Solutions Limited
116 - Industry AVG

Pay Structure
on an average salary of £57.2k, the company has an equivalent pay structure (£63.4k)
£57.2k - Sterling Pharma Solutions Limited
£63.4k - Industry AVG

Efficiency
resulting in sales per employee of £176.6k, this is less efficient (£414.6k)
£176.6k - Sterling Pharma Solutions Limited
£414.6k - Industry AVG

Debtor Days
it gets paid by customers after 212 days, this is later than average (63 days)
212 days - Sterling Pharma Solutions Limited
63 days - Industry AVG

Creditor Days
its suppliers are paid after 32 days, this is close to average (32 days)
32 days - Sterling Pharma Solutions Limited
32 days - Industry AVG

Stock Days
it holds stock equivalent to 67 days, this is less than average (107 days)
67 days - Sterling Pharma Solutions Limited
107 days - Industry AVG

Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (9 weeks)
2 weeks - Sterling Pharma Solutions Limited
9 weeks - Industry AVG

Debt Level
it has a ratio of liabilities to total assets of 85.7%, this is a higher level of debt than the average (43.6%)
85.7% - Sterling Pharma Solutions Limited
43.6% - Industry AVG
STERLING PHARMA SOLUTIONS LIMITED financials

Sterling Pharma Solutions Limited's latest turnover from March 2024 is £115.5 million and the company has net assets of £51.8 million. According to their latest financial statements, Sterling Pharma Solutions Limited has 654 employees and maintains cash reserves of £8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 115,470,000 | 130,411,000 | 118,573,000 | 82,449,000 | 68,206,000 | 56,444,000 | 55,428,000 | 37,853,000 | 31,902,000 | 22,903,000 | 28,776,000 | 34,505,000 | 42,171,000 | 37,240,000 | 31,746,000 |
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost Of Sales | 85,088,000 | 84,276,000 | 75,836,000 | 58,619,000 | 50,862,000 | 45,272,000 | 41,865,000 | 32,343,000 | 28,184,000 | 23,572,000 | 27,229,000 | 28,798,000 | 34,328,000 | 31,884,000 | 30,365,000 |
Gross Profit | 30,382,000 | 46,135,000 | 42,737,000 | 23,830,000 | 17,344,000 | 11,172,000 | 13,563,000 | 5,510,000 | 3,718,000 | -669,000 | 1,547,000 | 5,707,000 | 7,843,000 | 5,356,000 | 1,381,000 |
Admin Expenses | 24,216,000 | 15,951,000 | 11,512,000 | 7,251,000 | 3,215,000 | 2,862,000 | 2,389,000 | 1,369,000 | 1,154,000 | 800,000 | 930,000 | 1,112,000 | 1,200,000 | 1,646,000 | 3,252,000 |
Operating Profit | 6,166,000 | 30,184,000 | 31,225,000 | 16,579,000 | 14,129,000 | 8,310,000 | 11,174,000 | 4,141,000 | 2,564,000 | -1,469,000 | 617,000 | 4,595,000 | 6,643,000 | 3,710,000 | -1,871,000 |
Interest Payable | 22,631,000 | 15,208,000 | 9,570,000 | 7,812,000 | 3,489,000 | 1,990,000 | 1,546,000 | 1,689,000 | 1,281,000 | 1,022,000 | 999,000 | 863,000 | 1,706,000 | 1,840,000 | 1,715,000 |
Interest Receivable | 5,229,000 | 5,010,000 | 2,876,000 | 1,569,000 | 415,000 | 94,000 | 0 | 0 | 0 | 0 | 0 | 18,000 | 34,000 | 26,000 | 18,000 |
Pre-Tax Profit | -11,236,000 | 19,986,000 | 24,531,000 | 10,336,000 | 11,055,000 | -1,169,000 | 9,628,000 | 2,452,000 | 1,283,000 | -2,491,000 | -382,000 | 3,750,000 | 4,971,000 | 1,896,000 | -2,219,000 |
Tax | 2,387,000 | -3,353,000 | -4,145,000 | -2,312,000 | -2,080,000 | -94,000 | -1,780,000 | 76,000 | -139,000 | -185,000 | 390,000 | -4,000 | 667,000 | 915,000 | 0 |
Profit After Tax | -8,849,000 | 16,633,000 | 20,386,000 | 8,024,000 | 8,975,000 | -1,263,000 | 7,848,000 | 2,528,000 | 1,144,000 | -2,676,000 | 8,000 | 3,746,000 | 5,638,000 | 2,811,000 | -2,219,000 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 3,282,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | -8,849,000 | 16,633,000 | 20,386,000 | 8,024,000 | 8,975,000 | -4,545,000 | 7,848,000 | 2,528,000 | 1,144,000 | -2,676,000 | 8,000 | 3,746,000 | 5,638,000 | 2,811,000 | -2,219,000 |
Employee Costs | 37,399,000 | 35,280,000 | 30,618,000 | 26,370,000 | 19,408,000 | 21,680,000 | 16,032,000 | 13,921,000 | 12,591,000 | 11,776,000 | 11,846,000 | 12,083,000 | 12,525,000 | 11,931,000 | 11,796,000 |
Number Of Employees | 654 | 624 | 560 | 494 | 417 | 388 | 366 | 333 | 299 | 272 | 279 | 296 | 304 | 299 | 278 |
EBITDA* | 12,592,000 | 34,575,000 | 35,381,000 | 18,632,000 | 16,400,000 | 10,093,000 | 12,304,000 | 4,818,000 | 3,941,000 | -192,000 | 3,273,000 | 7,308,000 | 8,910,000 | 5,300,000 | -534,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 84,766,000 | 83,488,000 | 70,286,000 | 58,717,000 | 41,311,000 | 27,531,000 | 21,786,000 | 15,630,000 | 13,977,000 | 12,470,000 | 12,190,000 | 12,491,000 | 13,275,000 | 12,487,000 | 12,212,000 |
Intangible Assets | 468,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,000 | 250,000 | 517,000 | 1,046,000 | 1,576,000 | -232,000 |
Investments & Other | 112,705,000 | 107,179,000 | 60,181,000 | 60,145,000 | 3,772,000 | 3,772,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 61,279,000 | 32,684,000 | 42,468,000 | 29,771,000 | 6,234,000 | 4,743,000 | 375,000 | 0 | 1,018,000 | 1,897,000 | 1,968,000 | 1,582,000 | 0 | 0 | 0 |
Total Fixed Assets | 259,218,000 | 223,351,000 | 172,935,000 | 148,633,000 | 51,317,000 | 36,046,000 | 22,161,000 | 15,630,000 | 14,995,000 | 14,375,000 | 14,408,000 | 14,590,000 | 14,321,000 | 14,063,000 | 11,980,000 |
Stock & work in progress | 15,683,000 | 18,462,000 | 17,935,000 | 12,919,000 | 8,881,000 | 7,545,000 | 4,773,000 | 5,149,000 | 3,431,000 | 2,753,000 | 2,203,000 | 2,549,000 | 3,050,000 | 2,909,000 | 4,823,000 |
Trade Debtors | 67,135,000 | 70,880,000 | 53,772,000 | 35,819,000 | 22,900,000 | 21,505,000 | 16,968,000 | 14,756,000 | 12,066,000 | 9,947,000 | 7,204,000 | 5,428,000 | 6,523,000 | 9,960,000 | 9,170,000 |
Group Debtors | 3,146,000 | 759,000 | 968,000 | 823,000 | 398,000 | 237,000 | 100,000 | 32,000 | 496,000 | 300,000 | 153,000 | 107,000 | 242,000 | 227,000 | 1,680,000 |
Misc Debtors | 7,600,000 | 8,054,000 | 5,136,000 | 4,976,000 | 3,763,000 | 4,866,000 | 4,566,000 | 4,656,000 | 3,265,000 | 2,260,000 | 4,909,000 | 2,810,000 | 5,511,000 | 2,268,000 | 1,941,000 |
Cash | 8,045,000 | 1,990,000 | 2,210,000 | 7,132,000 | 5,820,000 | 7,131,000 | 1,359,000 | 1,468,000 | 52,000 | 7,000 | 141,000 | 166,000 | 614,000 | 188,000 | 199,000 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 101,609,000 | 100,145,000 | 80,021,000 | 61,669,000 | 41,762,000 | 41,284,000 | 27,766,000 | 26,061,000 | 19,310,000 | 15,267,000 | 14,610,000 | 11,060,000 | 15,940,000 | 15,552,000 | 17,813,000 |
total assets | 360,827,000 | 323,496,000 | 252,956,000 | 210,302,000 | 93,079,000 | 77,330,000 | 49,927,000 | 41,691,000 | 34,305,000 | 29,642,000 | 29,018,000 | 25,650,000 | 30,261,000 | 29,615,000 | 29,793,000 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,927,000 | 8,583,000 | 15,788,000 | 10,095,000 | 10,516,000 | 11,663,000 | 7,548,000 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 11,156,000 | 9,062,000 | 1,125,000 | 1,375,000 | 0 | 0 | 0 | 0 | 6,113,000 |
Trade Creditors | 7,509,000 | 15,537,000 | 11,569,000 | 5,987,000 | 5,006,000 | 6,087,000 | 5,585,000 | 7,718,000 | 4,573,000 | 3,156,000 | 2,622,000 | 2,146,000 | 4,600,000 | 3,430,000 | 4,796,000 |
Group/Directors Accounts | 134,073,000 | 106,657,000 | 76,749,000 | 63,655,000 | 47,315,000 | 44,338,000 | 552,000 | 661,000 | 9,422,000 | 9,014,000 | 951,000 | 865,000 | 2,635,000 | 6,067,000 | 6,920,000 |
other short term finances | 950,000 | 1,222,000 | 320,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 92,000 | 190,000 | 291,000 | 338,000 | 367,000 | 278,000 | 217,000 | 88,000 | 37,000 | 31,000 | 0 | 0 | 0 | 0 |
other current liabilities | 17,475,000 | 30,119,000 | 30,760,000 | 30,925,000 | 16,244,000 | 10,995,000 | 7,601,000 | 6,111,000 | 2,396,000 | 2,852,000 | 2,049,000 | 2,423,000 | 5,398,000 | 6,816,000 | 6,444,000 |
total current liabilities | 160,007,000 | 153,627,000 | 119,588,000 | 100,858,000 | 68,903,000 | 61,787,000 | 25,172,000 | 23,769,000 | 23,531,000 | 25,017,000 | 21,441,000 | 15,529,000 | 23,149,000 | 27,976,000 | 31,821,000 |
loans | 135,337,000 | 92,685,000 | 0 | 75,730,000 | 0 | 0 | 6,527,000 | 8,445,000 | 4,807,000 | 0 | 0 | 2,375,000 | 3,550,000 | 3,750,000 | 2,750,000 |
hp & lease commitments | 0 | 0 | 0 | 292,000 | 578,000 | 920,000 | 739,000 | 788,000 | 411,000 | 114,000 | 155,000 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 322,000 | 417,000 | 516,000 | 496,000 | 828,000 | 390,000 | 355,000 | 499,000 |
other liabilities | 0 | 0 | 75,822,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 13,691,000 | 16,543,000 | 13,538,000 | 9,800,000 | 8,000,000 | 8,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 149,028,000 | 109,228,000 | 89,360,000 | 85,822,000 | 8,578,000 | 8,920,000 | 7,266,000 | 9,555,000 | 5,635,000 | 630,000 | 651,000 | 3,203,000 | 3,940,000 | 4,105,000 | 3,249,000 |
total liabilities | 309,035,000 | 262,855,000 | 208,948,000 | 186,680,000 | 77,481,000 | 70,707,000 | 32,438,000 | 33,324,000 | 29,166,000 | 25,647,000 | 22,092,000 | 18,732,000 | 27,089,000 | 32,081,000 | 35,070,000 |
net assets | 51,792,000 | 60,641,000 | 44,008,000 | 23,622,000 | 15,598,000 | 6,623,000 | 17,489,000 | 8,367,000 | 5,139,000 | 3,995,000 | 6,926,000 | 6,918,000 | 3,172,000 | -2,466,000 | -5,277,000 |
total shareholders funds | 51,792,000 | 60,641,000 | 44,008,000 | 23,622,000 | 15,598,000 | 6,623,000 | 17,489,000 | 8,367,000 | 5,139,000 | 3,995,000 | 6,926,000 | 6,918,000 | 3,172,000 | -2,466,000 | -5,277,000 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | 6,166,000 | 30,184,000 | 31,225,000 | 16,579,000 | 14,129,000 | 8,310,000 | 11,174,000 | 4,141,000 | 2,564,000 | -1,469,000 | 617,000 | 4,595,000 | 6,643,000 | 3,710,000 | -1,871,000 |
Depreciation | 6,426,000 | 4,391,000 | 4,156,000 | 2,053,000 | 2,271,000 | 1,783,000 | 1,130,000 | 677,000 | 1,369,000 | 1,035,000 | 2,165,000 | 2,183,000 | 1,737,000 | 1,641,000 | 1,444,000 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,000 | 242,000 | 491,000 | 530,000 | 530,000 | -51,000 | -107,000 |
Tax | 2,387,000 | -3,353,000 | -4,145,000 | -2,312,000 | -2,080,000 | -94,000 | -1,780,000 | 76,000 | -139,000 | -185,000 | 390,000 | -4,000 | 667,000 | 915,000 | 0 |
Stock | -2,779,000 | 527,000 | 5,016,000 | 4,038,000 | 1,336,000 | 2,772,000 | -376,000 | 1,718,000 | 678,000 | 550,000 | -346,000 | -501,000 | 141,000 | -1,914,000 | 4,823,000 |
Debtors | 26,783,000 | 10,033,000 | 30,955,000 | 38,094,000 | 1,944,000 | 9,342,000 | 2,565,000 | 2,599,000 | 2,441,000 | 170,000 | 4,307,000 | -2,349,000 | -179,000 | -336,000 | 12,791,000 |
Creditors | -8,028,000 | 3,968,000 | 5,582,000 | 981,000 | -1,081,000 | 502,000 | -2,133,000 | 3,145,000 | 1,417,000 | 534,000 | 476,000 | -2,454,000 | 1,170,000 | -1,366,000 | 4,796,000 |
Accruals and Deferred Income | -12,644,000 | -641,000 | -165,000 | 14,681,000 | 5,249,000 | 3,394,000 | 1,168,000 | 3,620,000 | -555,000 | 823,000 | -706,000 | -2,537,000 | -1,383,000 | 228,000 | 6,943,000 |
Deferred Taxes & Provisions | -2,852,000 | 3,005,000 | 3,738,000 | 1,800,000 | 0 | 8,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | -32,549,000 | 26,994,000 | 4,420,000 | -8,350,000 | 15,208,000 | 9,781,000 | 7,370,000 | 7,342,000 | 1,545,000 | 260,000 | -528,000 | 5,163,000 | 9,402,000 | 7,327,000 | -6,409,000 |
Investing Activities | |||||||||||||||
capital expenditure | -7,358,000 | -1,688,000 | -2,474,000 | ||||||||||||
Change in Investments | 5,526,000 | 46,998,000 | 36,000 | 56,373,000 | 0 | 3,772,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | -7,358,000 | -1,688,000 | -2,474,000 | ||||||||||||
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | -11,156,000 | 2,094,000 | 7,937,000 | -250,000 | 1,375,000 | 0 | 0 | 0 | -6,113,000 | 6,113,000 |
Group/Directors Accounts | 27,416,000 | 29,908,000 | 13,094,000 | 16,340,000 | 2,977,000 | 43,786,000 | -109,000 | -8,761,000 | 408,000 | 8,063,000 | 86,000 | -1,770,000 | -3,432,000 | -853,000 | 6,920,000 |
Other Short Term Loans | -272,000 | 902,000 | 320,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 42,652,000 | 92,685,000 | -75,730,000 | 75,730,000 | 0 | -6,527,000 | -1,918,000 | 3,638,000 | 4,807,000 | 0 | -2,375,000 | -1,175,000 | -200,000 | 1,000,000 | 2,750,000 |
Hire Purchase and Lease Commitments | -92,000 | -98,000 | -393,000 | -333,000 | -371,000 | 270,000 | 12,000 | 506,000 | 348,000 | -35,000 | 186,000 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | -75,822,000 | 75,822,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | -17,402,000 | -10,198,000 | -6,694,000 | -6,243,000 | -3,074,000 | -1,896,000 | -1,546,000 | -1,689,000 | -1,281,000 | -1,022,000 | -999,000 | -845,000 | -1,672,000 | -1,814,000 | -1,697,000 |
cash flow from financing | 52,302,000 | 37,377,000 | 6,419,000 | 85,494,000 | -468,000 | 18,156,000 | -193,000 | 2,331,000 | 4,032,000 | 8,126,000 | -3,102,000 | -3,790,000 | -5,304,000 | -7,780,000 | 11,028,000 |
cash and cash equivalents | |||||||||||||||
cash | 6,055,000 | -220,000 | -4,922,000 | 1,312,000 | -1,311,000 | 5,772,000 | -109,000 | 1,416,000 | 45,000 | -134,000 | -25,000 | -448,000 | 426,000 | -11,000 | 199,000 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5,927,000 | -2,656,000 | -7,205,000 | 5,693,000 | -421,000 | -1,147,000 | 4,115,000 | 7,548,000 |
change in cash | 6,055,000 | -220,000 | -4,922,000 | 1,312,000 | -1,311,000 | 5,772,000 | -109,000 | 7,343,000 | 2,701,000 | 7,071,000 | -5,718,000 | -27,000 | 1,573,000 | -4,126,000 | -7,349,000 |
sterling pharma solutions limited Credit Report and Business Information
Sterling Pharma Solutions Limited Competitor Analysis

Perform a competitor analysis for sterling pharma solutions limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in NE23 area or any other competitors across 12 key performance metrics.
sterling pharma solutions limited Ownership
STERLING PHARMA SOLUTIONS LIMITED group structure
Sterling Pharma Solutions Limited has 3 subsidiary companies.
Ultimate parent company
2 parents
STERLING PHARMA SOLUTIONS LIMITED
05712796
3 subsidiaries
sterling pharma solutions limited directors
Sterling Pharma Solutions Limited currently has 2 directors. The longest serving directors include Mr Kevin Cook (Oct 2014) and Mr Matthew Anderson (Nov 2024).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Kevin Cook | 60 years | Oct 2014 | - | Director | |
Mr Matthew Anderson | United Kingdom | 53 years | Nov 2024 | - | Director |
P&L
March 2024turnover
115.5m
-11%
operating profit
6.2m
-80%
gross margin
26.4%
-25.62%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
51.8m
-0.15%
total assets
360.8m
+0.12%
cash
8m
+3.04%
net assets
Total assets minus all liabilities
sterling pharma solutions limited company details
company number
05712796
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
February 2006
age
19
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
shasun pharma solutions limited (September 2016)
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
dudley, cramlington, northumberland, NE23 7QG
Bank
-
Legal Advisor
-
sterling pharma solutions limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 22 charges/mortgages relating to sterling pharma solutions limited. Currently there are 3 open charges and 19 have been satisfied in the past.
sterling pharma solutions limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for STERLING PHARMA SOLUTIONS LIMITED. This can take several minutes, an email will notify you when this has completed.
sterling pharma solutions limited Companies House Filings - See Documents
date | description | view/download |
---|